

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Kevin Alexander, MD	Speaker	• None	• N/A
Quan Bui, MD	Speaker	Bristol Myers Squibb	Consultant
Scott Cameron, MD, PhD	Speaker	Inari, Inc. Sanofi	Fellowship SupportConsultant
Andrew Cheng, MD	Speaker	• None	• N/A
Sarah Cuddy, MB BCh BAO, MD	Speaker	Ionis PharmaceuticalsPfizer	ConsultantResearch Support
Margot Davis, MD	Speaker	 AstraZeneca, Bayer, Ferring Pharmaceuticals, Ionis Pharmaceuticals, Janssen Biotech, Novo Nordisk Pfizer Alnylam, Bayer, Boehringer Ingelheim/Lilly, Ferring Pharmaceuticals, Janssen Biotech, Pfizer 	ConsultantResearch SupportSpeakers Bureau
Dominic Ferrey, MD	Speaker	• None	• N/A
David Hermel, MD	Speaker	• None	• N/A
Rola Khedraki, MD	Course Co-Director, Moderator, Speaker	PfizerAlnylam, AstraZenecaBridgeBio	Advisory BoardSpeakerCommercial Steering Committee
Paul Kim, MD	Speaker	CareDx, Natera	Research Funding
David Kunkel, MD	Speaker	Evoke Pharma, Pfizer, ReStalsis, Phathom Pharmaceuticals, Ardelyx, Mahana Therapeutics, Takeda, GI Supply and Laborie, Regeneron, Vanda Pharmaceuticals	• Speaker
Ahmad Masri, MD	Speaker	 Attralus, Cytokinetics, Ionis, Pfizer Akros, Alexion, Alnylam, AstraZeneca, Attralus, BioMarin, Bristol Myers Squibb, Cytokinetics, Eidos/BridgeBio, Haya, Ionis, Lexicon, Pfizer, Prothena, Tenaya 	 Research Grants Clinical Trials Steering Committee, Consultant
Rajeev Mohan, MD	Course Co-Director, Moderator, Speaker	Axon Therapeutics, CORVIA, V WaveCareDx, Eidos Therapeutics	Research SupportConsultantSpeaker



Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
		Akcea/Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Pfizer	
Purvi Parwani, MBBS	Speaker	AstraZeneca, Medtronic, Inc.	• Consultant
Kalpit Shah, MD	Speaker	Emerging Surgical IncMission Surgical	ConsultantConsultant, Speaker
Marcus Urey, MD	Course Co-Director, Moderator, Speaker	 Alexion, Alnylam, AstraZeneca, BridgeBio, Cytokinetics, Pfizer Alexion, Ionis 	ConsultantResearch
CME Committee	CE approval, all final decision-making on activities	• None	• N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	• None	• N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.